Gossamer Bio Statistics
Total Valuation
Gossamer Bio has a market cap or net worth of $564.36 million. The enterprise value is $548.52 million.
Important Dates
The next estimated earnings date is Thursday, November 6, 2025, after market close.
Earnings Date | Nov 6, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Gossamer Bio has 229.88 million shares outstanding. The number of shares has increased by 4.01% in one year.
Current Share Class | 229.88M |
Shares Outstanding | 229.88M |
Shares Change (YoY) | +4.01% |
Shares Change (QoQ) | +0.20% |
Owned by Insiders (%) | 3.56% |
Owned by Institutions (%) | 61.44% |
Float | 185.26M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 14.09 |
Forward PS | 20.96 |
PB Ratio | n/a |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 13.63 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.40
Current Ratio | 4.40 |
Quick Ratio | 4.11 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -13.28 |
Financial Efficiency
Return on equity (ROE) is -783.37% and return on invested capital (ROIC) is -41.64%.
Return on Equity (ROE) | -783.37% |
Return on Assets (ROA) | -29.63% |
Return on Invested Capital (ROIC) | -41.64% |
Return on Capital Employed (ROCE) | -77.74% |
Revenue Per Employee | $277,497 |
Profits Per Employee | -$956,848 |
Employee Count | 145 |
Asset Turnover | 0.13 |
Inventory Turnover | n/a |
Taxes
Income Tax | -3.54M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +135.71% in the last 52 weeks. The beta is 1.95, so Gossamer Bio's price volatility has been higher than the market average.
Beta (5Y) | 1.95 |
52-Week Price Change | +135.71% |
50-Day Moving Average | 2.50 |
200-Day Moving Average | 1.50 |
Relative Strength Index (RSI) | 43.86 |
Average Volume (20 Days) | 4,075,650 |
Short Selling Information
The latest short interest is 23.99 million, so 10.44% of the outstanding shares have been sold short.
Short Interest | 23.99M |
Short Previous Month | 22.05M |
Short % of Shares Out | 10.44% |
Short % of Float | 12.95% |
Short Ratio (days to cover) | 5.60 |
Income Statement
In the last 12 months, Gossamer Bio had revenue of $40.24 million and -$138.74 million in losses. Loss per share was -$0.61.
Revenue | 40.24M |
Gross Profit | 40.24M |
Operating Income | -145.62M |
Pretax Income | -142.29M |
Net Income | -138.74M |
EBITDA | -145.29M |
EBIT | -145.62M |
Loss Per Share | -$0.61 |
Full Income Statement Balance Sheet
The company has $212.92 million in cash and $202.83 million in debt, giving a net cash position of $10.09 million or $0.04 per share.
Cash & Cash Equivalents | 212.92M |
Total Debt | 202.83M |
Net Cash | 10.09M |
Net Cash Per Share | $0.04 |
Equity (Book Value) | -46.11M |
Book Value Per Share | -0.20 |
Working Capital | 182.30M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$154.30 million and capital expenditures -$79,000, giving a free cash flow of -$154.38 million.
Operating Cash Flow | -154.30M |
Capital Expenditures | -79,000 |
Free Cash Flow | -154.38M |
FCF Per Share | -$0.67 |
Full Cash Flow Statement Margins
Gross Margin | 100.00% |
Operating Margin | -361.91% |
Pretax Margin | -353.62% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Gossamer Bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -4.01% |
Shareholder Yield | -4.01% |
Earnings Yield | -24.84% |
FCF Yield | -27.64% |
Analyst Forecast
The average price target for Gossamer Bio is $8.60, which is 250.31% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $8.60 |
Price Target Difference | 250.31% |
Analyst Consensus | Strong Buy |
Analyst Count | 6 |
Revenue Growth Forecast (5Y) | 27.89% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Gossamer Bio has an Altman Z-Score of -8.25. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -8.25 |
Piotroski F-Score | n/a |